Award & Investment Overview
The State University of New York has awarded $400,000 through its Technology Accelerator Fund to eight research projects across five SUNY campuses: University at Albany, Binghamton University, University at Buffalo, Stony Brook University, and SUNY Upstate Medical University.
The 2026 portfolio spans quantum sensing, cardiopulmonary monitoring, AI-enabled cancer diagnostics, RNA therapeutic delivery, power semiconductors, circadian disorder therapeutics, burn diagnostics, and targeted treatments for acute respiratory disease.
TAF provides seed grants to faculty inventors and scientists for commercialization-focused activities including feasibility studies, prototyping, testing, and other work needed to demonstrate commercial potential. Individual award amounts for the eight projects were not disclosed.
Since launching in 2011, SUNY reports that TAF has invested more than $5.1 million to advance the commercial readiness of 99 SUNY innovations. Those projects have subsequently attracted an additional $41 million from government agencies, industry licensees, and early-stage investors.
The 2026 awards are a direct example of institutional GAP funding. Rather than financing basic research, TAF targets the development work between academic discovery and the point at which technologies can attract licensees, strategic partners, customers, or outside investment.
Approach & Ecosystem Context
SUNY designed the Technology Accelerator Fund around a commercialization challenge common across university research portfolios: promising inventions frequently require additional evidence and development before external partners are prepared to commit resources.
TAF evaluates projects based on factors including intellectual property protection, marketability, commercial potential, feasibility, and potential impact. Funding can then support activities such as feasibility studies, prototypes, and testing that address specific commercialization uncertainties.
This structure places TAF squarely within the proof-of-concept and translational funding segment of the GAP ecosystem.
The program’s reported leverage is also significant from a commercialization perspective. More than $5.1 million in institutional TAF investment since 2011 has been associated with $41 million in subsequent funding from development partners. While follow-on capital cannot be attributed solely to the TAF awards, the progression illustrates the intended role of GAP funding: use relatively small amounts of early institutional capital to generate milestones that improve readiness for larger external commitments.
The 2026 portfolio also demonstrates the flexibility required of a system-wide GAP fund. A quantum photonics platform, therapeutic candidate, semiconductor transistor, AI diagnostic model, and medical imaging device require different validation milestones. TAF can address those differences by financing the specific technical or commercial evidence each project needs to advance.
Innovation & Technology
University at Albany: Scalable Platform for Room-Temperature Quantum Sensing and Imaging Technologies
Spyros Galis is developing a quantum photonics platform intended to operate at room temperature.
Many quantum photonic devices depend on cryogenic cooling, creating cost, energy, and system-complexity barriers to broader deployment. The project seeks to eliminate that requirement and create a more practical platform for quantum sensing and imaging applications.
University at Albany: CurrentView
Gary Saulnier is developing CurrentView, a bedside monitoring system for neonatal and pediatric patients with congenital heart disease and other cardiopulmonary conditions.
The technology uses non-invasive electrical measurements to continuously assess pulmonary perfusion and ventilation in three dimensions, potentially giving clinicians additional real-time information for treatment decisions.
Binghamton University: ClinSegAI
Nancy Guo developed ClinSegAI, an AI-based predictive platform designed to identify molecular biomarkers from standard pathology images.
The commercialization opportunity centers on reducing the time required to obtain information used in cancer treatment decisions by extracting biomarker predictions from existing imaging workflows.
Binghamton University: Lipid Nanoparticles for RNA Therapeutic Delivery
John Fetse is developing lipid nanoparticles incorporating amino acids directly into the lipid structure.
The approach is intended to address delivery efficiency and toxicity limitations associated with existing lipid nanoparticle systems for RNA therapeutics. TAF support will advance in vivo validation.
University at Buffalo: Gallium Oxide Semiconductor Transistors for Electric Vehicle and AI Power
Uttam Singisetti is developing gallium oxide-based high-power electronic devices intended to improve electricity conversion efficiency.
Potential markets include electric vehicles and AI data-center infrastructure, where increasing power requirements are creating demand for semiconductor technologies capable of reducing energy losses while maintaining high performance.
University at Buffalo: First In-Class Therapy for Advanced Phase Circadian Disorders
Margarita L. Dubocovich is developing an orally administered therapeutic intended to treat advanced-phase circadian disorders by realigning the underlying biological clock mechanism.
The project targets disorders associated with misalignment between an individual’s circadian rhythm and daily schedule or environment.
Stony Brook University: Terahertz Spectral Imaging for Diagnosis of Skin Burns
M. Hassan Arbab has developed a portable handheld scanner using terahertz spectral imaging to diagnose and triage burn injuries.
SUNY reports diagnostic accuracy of 93 to 95 percent or better for the technology, compared with approximately 60 to 65 percent for current clinical techniques. The commercialization pathway centers on translating that performance into a practical diagnostic device for clinical burn assessment.
SUNY Upstate Medical University: Lung-Targeting Drug Formulation for Acute Respiratory Disease
Yamin Li is developing lung-targeting lipid nanoparticles for treatment of sepsis-induced acute respiratory distress syndrome.
The approach is designed to concentrate treatment in the lungs, addressing a severe condition associated with lung injury, ventilator use, intensive care, and substantial mortality.
Related Topics
SUNY Technology Accelerator Fund, university GAP funding, proof-of-concept funding, translational research, university commercialization, technology transfer, University at Albany, Binghamton University, University at Buffalo, Stony Brook University, SUNY Upstate Medical University, quantum sensing, AI cancer diagnostics, RNA therapeutics, semiconductor technology, medical devices, burn diagnostics, respiratory therapeutics
About innovosource
innovosource tracks GAP programs, including proof-of-concept programs, startup accelerators, translational research initiatives, university venture funds, and commercialization ecosystems that help move university innovations from research to market.
Our coverage is informed by the Mind the GAP Initiative and the GAP COA consortium activity, providing practical insights into the evolving commercialization landscape.
Learn more:
Source
https://www.suny.edu/suny-news/press-releases/9-26/9-14-26/taf.html
